A systematic review of the psychosocial difficulties relevant to patients with migraine

Journal of Headache and Pain

Volumn 13, Issue 8, 2012, Pages 595-606

  Raggi, Alberto ^a   Giovannetti, Ambra Mara ^a   Quintas, Rui ^a   D'Amico, Domenico ^a   Cieza, Alarcos ^b,c,d   Sabariego, Carla ^b   Bickenbach, Jerome Edmound ^c   Leonardi, Matilde ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MUNICH   (Germany)

^c SWISS PARAPLEGIC RESEARCH   (Switzerland)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Disability; Headaches frequency; Migraine; Pain; Preventive treatment; Symptomatic treatment

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; ELETRIPTAN; HISTAMINE; METOPROLOL; NAPROXEN; NEBIVOLOL; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; ZOLMITRIPTAN;

COST OF ILLNESS; DISABILITY; EMOTIONAL DISORDER; EMPLOYMENT; FATIGUE; HEADACHE; HUMAN; JOB PERFORMANCE; MENTAL HEALTH; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PAIN; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SOCIAL STATUS; SYSTEMATIC REVIEW;

BEHAVIORAL SYMPTOMS; DATABASES, FACTUAL; EMPLOYMENT; HUMANS; MENTAL DISORDERS; MIGRAINE DISORDERS; SOCIAL BEHAVIOR DISORDERS;

EID: 84870337951     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-012-0482-1     Document Type: Review

References (83)

1. Headache Classification Subcommittee of the International Headache Society (2004) Classification of headache disorders, 2nd ed. Cephalalgia 24:9-160
2. Stovner LJ, Andree C, Eurolight Steering Committee (2010) Prevalence of headache in Europe: A review for the Eurolight project. J Headache Pain 11:289-299
3. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2012) The cost of headache disorders in Europe: The Eurolight project. Eur J Neurol 19:703-711
4. Freitag F (2007) The cycle of migraine: Patients' quality of life during and between migraine attacks. Clin Ther 29:939-949
5. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and healthrelated quality-of-life: A population-based case-control study from England. Cephalalgia 23:441-450
6. Lj Stovner, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 27:193-210
7. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D'Amico D (2004) Disability and quality of life in different primary headaches: Results from Italian studies. Neurol Sci 25:S105-S107
8. Leonardi M, Steiner TJ, Scher AT, Lipton RB (2005) The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 6:429-440
9. Mula M, Viana M, Jauch R, Schmitz B, Bettucci D, Cavanna AE, Strigaro G, Tota MG, Israel H, Reuter U, Monaco F (2009) Health-related quality of life measures and psychiatric comorbidity in patients with migraine. Eur J Neurol 16:1017-1021
10. Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50-S58
11. Leonardi M, Raggi A, Bussone G, D'Amico D (2010) Healthrelated quality of life, disability and severity of disease patients with migraine attending to a specialty headache center. Headache 50:1576-1586
12. Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003) The family impact of migraine: Populationbased studies in the USA and UK. Cephalagia 23:429-440
13. Smitherman TA, Ward TN (2011) Psychosocial factors of relevance to sex and gender studies in headache. Headache 51:923-931
14. World Health Organization (2001) The International Classification of Functioning, Disability and Health-ICF. WHO, Geneva
15. Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1-98
16. National Institute for Mental Health and Clinical Excellence (2009) The guideline manual. NICE, London
17. Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustün B, Stucki G (2005) ICF linking rules: An update based on lessons learned. J Rehabil Med 37:212-218
18. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S (2006) Guidance on the conduct of Narrative synthesis in systematic Reviews. A Product from the ESCR Methods Programme ESRC Methods Program, Lancaster 19. Cabello M, Mellor-Marsá B, Sabariego C, Cieza A, Bickenbach J, Ayuso-Mateos JL (2012) Psychosocial features of depression: A systematic literature review. J Affect Disord 141:22-33
19. Farmer K, Cady R, Bleiberg J, Reeves D, Putnam G, O'Quinn S, Batenhorst A (2001) Sumatriptan nasal spray and cognitive function during migraine: Results of an open-label study. Headache 41:377-384
20. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer (2000) Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 20:830-834
21. Mulder EJ, Passchier J, Linssen WH, de Geus EJ (2001) Effects of medication use on health state in postictal migraineurs. Headache 41:782-791
22. Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ (2006) Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 81:1311-1319
23. Garcia-Monco JC, Foncea N, Bilbao A, Ruiz de Velasco I, Gomez-Beldarrain M (2007) Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia 27:920-928
24. Fuh JL, Wang SJ (2006) Comparison of Short Form-36 and Migraine Disability Assessment questionnaire in patients with migraine. Clin J Pain 22:564-568
25. Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, AEGIS Investigator Study Group (2008) Effect of early intervention with almotriptan vs. placebo on migraine-associated functional disability: Results from the AEGIS Trial. Headache 48:341-354
26. Santanello NC, Davies G, Allen C, Kramer M, Lipton R (2002) Determinants of migraine-specific quality of life. Cephalalgia 22:680-685
27. Burk CT, Gilderman A, Salas J, Berenbeim D, Nichol MB (2003) The impact of an over-the counter migraine medication program on quality of life. Headache 43:191-201
28. Bordini CA, Mariano da Silva H, Garbelini RP, Teixeira SO, Speciali JG (2005) Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain 6:387-391
29. D'Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani F, De Marco R, Massetto N, Bussone G, Progetto Cefalee Lombardia Group (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691-696
30. Lainez MJ, Lopez A, Pascual AM (2005) Effects on productivity and quality of life of rizatriptan for acute migraine: A workplace study. Headache 45:883-890
31. Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L (2007) The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 5:56
32. Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48:900-913
33. Gori S, Morelli N, Maestri M, Fabbrini M, Bonanni E, Murri L (2005) Sleep quality, chronotypes and preferential timing of attacks in migraine without aura. J Headache Pain 6:258-260
34. Lucas C, Geraud G, Valade D, Chautard MH, Lantéri-Minet M (2006) Recognition and therapeutic management of migraine in 2004, in France: Results of FRAMIG 3, a French nationwide population-based survey. Headache 46:715-725
35. Calandre EP, Bembibre J, Arnedo ML, Becerra D (2002) Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients: Their relationship with the clinical manifestations of the illness. Cephalalgia 22:291-302
36. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, quality of life, and depression: A populationbased case-control study. Neurology 55:629-635
37. Vasudeva S, Claggett AL, Tietjen GE, McGrady AV (2003) Biofeedback-assisted relaxation in migraine headache: Relationship to cerebral blood flow velocity in the middle cerebral artery. Headache 43:245-250
38. Pradalier A, Lanteri-Minet M, Geraud G, Allain H, Lucas C, Delgado A (2004) The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 18:1149-1463
39. Vos J, Passchier J (2003) Reduced impact of migraine in everyday life: An observational study in the Dutch Society of Headache Patients. Headache 43:645-650
40. Nicholson R, Nash J, Andrasik F (2005) A self-administered behavioral intervention using tailored messages for migraine. Headache 45:1124-1239
41. Smith T, Blumenthal H, Diamond M, Mauskop A, Ames M, McDonald S, Lener S, Burch S (2007) Sumatriptan/Naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes. Headache 47:683-692
42. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, CAPSS-277 Investigator Group (2009) Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 31:542-559
43. Lawler SP, Cameron LD (2006) A randomized, controlled trial of massage therapy as a treatment for migraine. Ann Behav Med 32:50-59
44. John PJ, Sharma N, Sharma CM, Kankane A (2007) Effectiveness of yoga therapy in the treatment of migraine without aura: A randomized controlled trial. Headache 47:654-661
45. Sculpher M, Millson D, Meddis D, Poole L (2002) Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) study. Pharmacoeconomics 20:91-100
46. Lofland JH, Kim SS, Batenhorst AS, Johnson NE, Chatterton ML, Cady RK, Kaniecki R, Nash DB (2001) Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 76:1093-1101
47. Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS (2007) Efficacy of eletriptan in migraine-related functional impairment: Functional and work productivity outcomes. Headache 47:673-682
48. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, ErtasM, Lanteri-MinetM, Reuter U, Sánchez Del RíoM, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054-1062
49. Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K (2008) Nebivolol and metoprolol for treating migraine: An advance on beta-blocker treatment? Headache 48:118-125
50. Guyuron B, Kriegler JS, Davis J, Amini SB (2005) Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 115:1-9
51. Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S (2009) A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg 124:461-468
52. Lee ST, Park JH, Kim M (2005) Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: A randomized, prospective, parallel group, double-blind, placebocontrolled study. Headache 45:1004-1011
53. Dowson A, Bundy M, Salt R, Kilminster S (2007) Patient preference for triptan formulations: A prospective study with zolmitriptan. Headache 47:1144-1151
54. Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC (2005) Topiramate improves health-related quality of life when used to prevent migraine. Headache 45:1023-1230
55. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Gutie ́rrez I, Rivera-Castano L, Trujillo-Hernández B, Baltazar LM (2008) Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur Neurol 59:237-242
56. Narin SO, Pinar L, Erbas D, Oztürk V, Idiman F (2003) The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil 17:624-630
57. Rigatelli G, Cardaioli P, Giordan M, Dell'Avvocata F, Braggion G, Chianaglia M, Roncon L (2009) Transcatheter interatrial shunt closure as a cure for migraine: Can it be justified by paradoxical embolism-risk-driven criteria? Am J Med Sci 337:179-181
58. Merelle SY, Sorbi MJ, van Doornen LJ, Passchier J (2008) Lay trainers with migraine for a home-based behavioral training: A 6-month follow-up study. Headache 48:1311-1325
59. Lemstra M, Stewart B, Olszynski WP (2002) Effectiveness of multidisciplinary intervention in the treatment of migraine: A randomized clinical trial. Headache 42:845-854
60. Stronks DL, Tulen JH, Bussmann HB, Mulder LJ, Passchier J (2003) Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: A randomized, doubleblind, double-dummy, crossover study. Headache 43:845-852
61. WacogneC,Lacoste JP,GuillibertE,HuguesFC, LeJeunneC(2003) Stress, anxiety, depression and migraine. Cephalalgia 23:451-455
62. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA 289:65-69
63. Frediani F, Martelletti P, Bussone G (2004) Measure of negative impact of migraine on daily activities, social relationships and therapeutic approach. Neurol Sci 25:S249-S250
64. Holroyd KA, Drew JB, Cottrell CK, Romanek KM, Heh V (2007) Impaired functioning and quality of life in severe migraine: The role of catastrophizing and associated symptoms. Cephalalgia 27:1156-1165
65. Barbanti P, Fabbrini G, Aurilia C, Vanacore N, Cruccu G (2007) A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia 27:1115-1119
66. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Rivera-Castano L, Garcia-Solorzano A, López-Blanca C, Membrila-Maldonado M, Munoz-Solis R (2007) Subcutaneous histamine versus sodium valproate in migraine prophylaxis: A randomized, controlled, double-blind study. Eur J Neurol 14:1079-1084
67. Park JW, Shin HE, Kim JS, Lee KS (2008) Assessing migraine disability by diary-based measurement: Relationship to the characteristics of individual headache attacks. Eur J Neurol 15:817-821
68. Geraud G, Valade D, Lanteri-Minet M, Radat F, Lucas C, Vives E, Joubert JM, Mekies C (2008) SMILE: First observational prospective cohort study of migraine in primary care in France. Description of methods and study population. Cephalalgia 28:164-173
69. Varkey E, Cider A, Carlsson J, Linde M (2009) A study to evaluate the feasibility of an aerobic exercise program in patients with migraine. Headache 49:563-570
70. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988-994
71. Franzini A, Messina G, Cordella R, Marras C, Broggi G (2010) Deep brain stimulation of the posteromedial hypothalamus: Indications, long-term results, and neurophysiological considerations. Neurosurg Focus 29:E13
72. Proietti Cecchini A, Leone M, Manzoni GC, Torelli P, Bussone G (2012) Drug-resistant chronic migraine: The Italian GON project. Neurol Sci 33:S33-S36
73. Cecchini AP, Mea E, Tullo V, Curone M, Franzini A, Broggi G, Savino M, Bussone G, Leone M (2009) Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Preliminary data. Neurol Sci 30:S101-S104
74. Berger A, Bloudek LM, Varon SF, Oster G (2012). Adherence with Migraine Prophylaxis in Clinical Practice. Pain Pract 12:541-549
75. Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME (2010) Adherence to acute migraine medication: What does it mean, why does it matter? Headache 50:117-129
76. D'Amico D, Tepper SJ (2008) Prophylaxis of migraine: General principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155-1167
77. Moschiano F, D'Amico D, Canavero I, Pan I, Micieli G, Bussone G (2011) Migraine and depression: Common pathogenetic and therapeutic ground? Neurol Sci 32:S85-S88
78. Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A (2011) Migraine and psychiatric comorbidity: A review of clinical findings. J Headache Pain 12:115-125
79. Pompili M, Serafini G, Del Casale A, Rigucci S, Innamorati M, Girardi P, Tatarelli R, Lester D (2009) Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 9:985-1004
80. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J (2011) Association between migraine, lifestyle and socioeconomic factors: A population-based cross-sectional study. J Headache Pain 12:157-172
81. Winter AC, Hoffmann W, Meisinger C, Evers S, Vennemann M, Pfaffenrath V, Fendrich K, Baumeister SE, Kurth T, Berger K (2011) Association between lifestyle factors and headache. J Headache Pain 12:147-155
82. Gaul C, van Doorn C, Webering N, Dlugaj M, Katsarava Z, Diener HC, Fritsche G (2011) Clinical outcome of a headachespecific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: An observational study. J Headache Pain 12:475-483
83. Ware JE (2000) SF-36 health survey update. Spine 25:3130-3139